BCIQ Profiles

Company Profile ReportTarget Profile Report

Verona reports Phase IIa data for RPL554 in COPD

Verona Pharma plc (LSE:VRP; NASDAQ:VRNA) reported top-line data from a Phase IIa trial in patients with chronic obstructive pulmonary disease (COPD) showing that twice-daily

Read the full 246 word article

How to gain access

Continue reading with a
two-week free trial.